Mobile

A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients with Active Rheumatoid Arthritis Despite Methotrexate Thera...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003983-73

A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the safety and tolerability of RWJ-445380 at doses of 100, 200, or 300 mg/day for up to 12 weeks in patients with active Rheumatoid Arthritis (RA) despite methotrexate (MTX) therapy.

Critère d'inclusion

  • Rheumatoid Arthritis

Liens